Abstract
Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Current Cancer Therapy Reviews
Title:Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Volume: 11 Issue: 2
Author(s): Rony Benson, Supriya Mallick, K.P. Haresh, P.K. Julka and G.K. Rath
Affiliation:
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Abstract: Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Export Options
About this article
Cite this article as:
Benson Rony, Mallick Supriya, Haresh K.P., Julka P.K. and Rath G.K., Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203201
DOI https://dx.doi.org/10.2174/1573394711666151022203201 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Gene Therapy of Chronic Pain
Current Gene Therapy Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
Current Cancer Drug Targets Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research